TrialAnnals of oncology : official journal of the European Society for Medical Oncology2015

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.

P G Nuciforo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.